We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lentigen and Evrogen Enter License Agreement
News

Lentigen and Evrogen Enter License Agreement

Lentigen and Evrogen Enter License Agreement
News

Lentigen and Evrogen Enter License Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lentigen and Evrogen Enter License Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lentigen Corporation and Evrogen JSC have announced a licensing agreement whereby Lentigen will obtain access to certain fluorescent protein technologies.

Such technologies will enable the Company to expand customer service opportunities related to the design and manufacturing of its proprietary lentiviral vectors.

Access to these fluorescent technologies, including TurboGFP (green fluorescent protein), phi YFP (yellow) and J-Red (Red) will allow Lentigen to create lentiviral vectors with a multiple of fluorescent possibilities for customers who purchase its custom lentiviral vectors.

"This license agreement represents another important offering for Lentigen customers," remarked Dr. Boro Dropulic, Founder and CEO of Lentigen.

"These technologies expand the opportunities now available to Lentigen and our customers by providing additional research capabilities to our lentiviral vector technology."

"Lentigen aims to license additional technologies which add to the usefulness of our lentiviral vectors for both research and therapeutic purposes."

Dr. Sergey Lukyanov, Evrogen's Chief Scientific Officer, said, "We are pleased to have established the license agreement and collaboration with Lentigen Corporation to further expand the adoption and availability of novel fluorescent protein technology for life science researchers interested in new lentiviral products and related services."

Advertisement